In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?
Executive Summary
Regulatory and financial incentives have sparked major investment in orphan drug development, but now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?